Industry Hails ‘Common Sense’ FDA Rethink On Non-US Comparators For Biosimilars

New Guidance Eliminates Need For Three-Way PK Study

 
• By Dave Wallace
  
The guidance will make it easier for biosimilars developers to rely on non-US comparators (Shutterstock)

More from Biosimilars

More from Products